International Journal of Chronic Obstructive Pulmonary Disease. Dec/31/2013; 9: 303-314

Published online Mar/26/2014

PMID: 24707174

PMC: 3971913

doi: 10.2147/COPD.S38931

The role of microparticles in chronic obstructive pulmonary disease

Toru Takahashi

Hiroshi Kubo

Abstract

Introduction

Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by nearly irreversible lung destruction which results in airflow limitation.1 The severity of the disease is determined according to the degree of airflow limitation, which is measured using forced expiratory volume in one second (FEV₁). However, there are several limitations in the use of FEV₁ to evaluate the daily condition and disease progression of COPD patients. First, the sensitivity of FEV₁ in evaluating daily condition is not high. Second, although both frequent exacerbation2–5 and bronchial hyperresponsiveness6 are associated with rapid FEV₁ decline, FEV₁ does not reflect these conditions. Third, clinical manifestations and radiological observations are variable among COPD patients even when the degree of airflow limitation is the same.7 For these reasons, new biomarkers for COPD are being sought.8

Accumulating evidence indicates that injured cells in the lung tissue are closely involved in the pathophysiology of COPD.9,10 In animal models, the administration of a vascular endothelial growth factor receptor inhibitor induced apoptosis of pulmonary capillary endothelial cells, leading to emphysematous changes.11 The number of apoptotic epithelial and endothelial cells is increased in emphysematous lungs compared with normal lungs.12 In addition, senescence of alveolar epithelial and endothelial cells is accelerated in patients with emphysema.13 Greater numbers of apoptotic lung cells are observed in lung tissues from COPD patients than in those from smokers without COPD.9,14,15 Furthermore, morphological and biochemical markers of autophagy are increased in the lungs of patients with COPD compared with normal lung tissue.16 These results indicate the importance of injured cells in the pathophysiology of lung destruction and COPD.

Activated or injured cells release chemical mediators, such as alarmins and microvesicles, into the circulation, and these mediators can potently modulate systemic immune responses.17–20 There are three major types of microvesicles, which are primarily distinguished by size: exosomes (40–100 nm), microparticles (MPs) (0.1–1.0 μm), and apoptotic bodies (1–3 μm). In this review, we focus on endothelium-derived MPs, which can be detected by their endothelial-specific antigens using fluorescence-activated cell sorting (FACS),18–23 and discuss their potential as biomarkers for COPD.

MPs

MPs are membrane vesicles that are released by budding or shedding from the plasma membrane of activated or injured cells in response to inflammation (Figure 1).18–23 MP release from platelets,24 red blood cells,25 endothelial cells, tumor cells,26,27 and leucocytes28 has been reported. Because MPs are shed membrane vesicles, the antigens expressed on the original cells are expressed on the membrane of the MPs. For example, CD144, CD31, and CD62E are expressed on endothelial cell-derived MPs, whereas CD31 and CD41 are expressed on platelet-derived MPs. Various stimuli, such as increased intracellular Ca²⁺²⁹ and the activation of protein kinase C (PKC)30 and purinergic receptors of adenosine triphosphate (ATP) such as the P₂X₇ and P₂Y receptors,31,32 increase the rate of MP release. The contents of MPs are also variable and can include nucleic acids, particularly messenger ribonucleic acid (mRNA) and microRNA,22 proteolytic enzymes such as metalloproteinases,33 tissue factors,34 and alarmins.35 Released MPs interact with their target cells by binding to the surface of the target cell via specific receptors, followed by direct fusion of the shedding vesicle with the plasma membrane of the target cell, endocytic uptake of the vesicle, and horizontal transfer of molecules and RNA to the target cell.20 MPs play many roles, including modulating the biological functions of cells.36 For example, during leukocyte activation and arrest, activated mast cells and platelets deliver chemoattractants to endothelial cells through circulating MPs.37 MPs also display proinflammatory and prothrombotic activities through the activation of Toll-like receptors and other signaling pathways.17,21 MPs are released from cells in response to various conditions or stimuli and may be heterogeneous.38

MPs and smoking

Smoking is the most important risk factor for COPD. Cigarette smoke increases autophagy16,39 and induces apoptosis and necrosis in lung cells.40–42 Smoking increases the levels of circulating MPs. In vitro studies have demonstrated that cigarette smoke extract induces the release of tissue factor-positive MPs as well as MPs with proteolytic activity attributed to matrix metalloproteinase-14 (MMP-14) from human macrophages in vitro.43,44 Incubating pulmonary microvascular endothelial cells or aortic endothelial cells with cigarette smoke extract induces the release of CD31⁺/CD41⁻ MPs and CD146⁺ MPs in vitro.40 Secondhand smoke exposure induces the rapid release of circulating CD144⁺ endothelial microparticles (EMPs), within a few hours.45 Other groups have reported that CD31⁺/CD42b⁻ EMPs are increased in healthy active smokers and further increased in active smokers with emphysema compared with healthy non-smokers.46

MPs and oxidative stress

Oxidative stress induced by cigarette smoke exposure or activated neutrophils and/or macrophages in response to infection is also involved in the pathophysiology of COPD.47,48 Oxidative stress induces MP release. H₂O₂ induces apoptosis in endothelial cells and the release of CD31⁺/CD41⁻ or CD146⁺ MPs from aortic and pulmonary microvascular endothelial cells in vitro.40 Plasma levels of glutathione peroxidase, a marker of oxidative stress, are correlated with increased levels of platelet-, erythrocyte-, and endothelial-derived MPs independent of other factors involved in endothelial injury in patients with metabolic disease.49

MPs and infection

Viral and/or bacterial infection was reported to be detected in up to 60% of COPD exacerbation and has been found to be associated with a rapid decline in lung function.50,51 Several articles reported the impact of infections on circulating MPs,52–55 and the number of circulating MPs is significantly increased by infection. Therefore, the presence of airway infection may induce MP release in patients with COPD exacerbation.

EMPs

EMPs are released from injured endothelial cells during apoptosis and cellular activation.19,56,57 EMPs are defined by the surface expression of endothelial antigens, such as CD144 (vascular endothelial [VE]-cadherin), CD31 (platelet endothelial cell adhesion molecule [PECAM]-1), CD62e (E-selectin), CD146 (melanoma cell adhesion molecule [MCAM]), and CD51 (vitronectin) (Table 1 and Figure 2). Circulating EMP numbers are increased in patients with vascular disorders such as cardiovascular diseases,58–60 vasculitis,61,62 thrombosis,63,64 renal failure,65–67 hyperlipidemia,68 and metabolic syndrome.69,70 The increase in circulating EMPs reflects the degree of endothelial injury in such conditions (Table 2).

In vitro studies have demonstrated that different stimuli, such as tumor necrosis factor α, H₂O₂, and cigarette smoke extract, induce the release of different types of EMPs from cultured endothelial cells. The pattern of EMP release in response to a specific stimulus differs depending on the type of endothelial cell.40 These observations suggest that different types of EMPs are released depending on the site of inflammation and the type of stimulus. Some clinical studies have compared two or more subtypes of EMPs in patients with specific diseases and observed differences in the types of released EMPs (Table 3). Although the clinical significance of these differences in EMP release remains unclear, the pattern of increased EMPs may reflect differences in inflammatory stimuli and the activated site in vivo.

VE-cadherin EMPs

VE-cadherin EMPs are defined as CD144⁺ MPs. VE-cadherin is expressed only on endothelial cells and is therefore the most specific marker for endothelial cells.71 In contrast to PECAM-1 and MCAM, VE-cadherin is specifically located at adherence junctions.72 VE-cadherin has been proposed to function as a gatekeeper of endothelial junctions.37,73 VE-cadherin does not support leukocyte migration but instead might function as an obstacle to migrating cells. Changes in the localization of VE-cadherin are associated with neutrophil migration and increased vascular permeability.74 The release of VE-cadherin EMPs may reflect the structural destruction of the endothelium rather than the inflammatory condition of the lung.

PECAM EMPs

PECAM-1 (CD31) is concentrated at endothelial junctions and is also expressed on the surfaces of platelets, neutrophils, and subsets of lymphocytes. In contrast to VE-cadherin, PECAM-1 is located outside of the adherence junctions on endothelial cells.72,75 Platelet-specific antigens such as CD41 or CD42b are used to distinguish PECAM EMPs from platelet-derived MPs; PECAM EMPs are defined as CD31⁺/CD41⁻ or CD42b⁻ MPs. PECAM-1 is not used to detect leukocyte-derived MPs because its expression on leukocytes is too low.76 PECAM-1 is a signaling molecule that plays diverse roles in vascular biology, including the regulation of platelet function, angiogenesis, T-cell and B-cell activation, endothelial cell permeability, and transmigration across the endothelium.37,77–81 Our in vitro study indicated that PECAM EMPs are released from pulmonary microvascular endothelial cells mainly in response to apoptosis induced by stimulation by H₂O₂ or cigarette smoke extract.40 In addition, a clinical study indicated that approximately 90% of PECAM EMPs also express annexin V in COPD82 and 60% of PECAM EMPs express annexin V in active smokers.46 Therefore, the released EMPs likely reflect the apoptosis of injured endothelial cells.

MCAM EMPs

MCAM EMPs are defined as CD146⁺ MPs. MCAM is an adhesion molecule found on endothelial cells that is involved in processes such as endothelial permeability, signaling transduction, cell migration, angiogenesis, and the immune response.83 MCAM is located outside of the adherence junctions; however, MCAM expression is not restricted to cell junctions and is detected on the apical side of cultured endothelial cells.72 MCAM has been detected not only on endothelial cells but also on other cell types such as melanoma cells,84 a subset of T and B lymphocytes and natural killer (NK) cells under pathological conditions,85 and pericytes.86 Thus, CD146⁺ MPs can be released from other cell types as well as endothelial cells. In addition, the expression of MCAM, another marker of endothelial injury, is also used to detect circulating endothelial cells.85,87 Thus, circulating endothelial cells can be confounded with MCAM EMPs in FACS analysis.88

E-selectin EMPs

E-selectin is expressed only on endothelial cells and E-selectin EMPs are defined as CD62e⁺ MPs. E-selectin is rapidly induced on activated endothelial cells a few hours after inflammatory stimulation, whereas VE-cadherin, PECAM-1, and MCAM are constitutively expressed on endothelial cells.89 E-selectin plays an important role in recruiting leukocytes to the site of injury during inflammation.37,77–81 In vitro studies have indicated that tumor necrosis factor α upregulates E-selectin expression on endothelial cells within a few hours, resulting in the increased release of E-selectin EMPs.40,90 Thus, the presence of E-selectin EMPs might reflect the degree of ongoing endothelial inflammation.

CD51 EMPs

CD51 is the integrin α chain and is also known as the vitronectin receptor α chain. CD51 forms a heterodimer with an integrin β3 chain, such as glycoprotein IIIa (GPIIIa) or the CD61 molecule, and binds to vitronectin, von Willebrand factor (vWF), and fibronectin.91 CD51 is found on endothelial cells, B lymphocytes, monocytes, macrophages, and platelets.92 CD51 plays important roles in leukocyte homing and rolling and angiogenesis.37,93 Although the specificity of endothelial origin is less than the other four EMP subtypes, CD51 MPs are defined as EMPs in some articles.94–96

COPD and EMPs

We examined the levels of VE-cadherin, PECAM, MCAM, and E-selectin EMPs in 80 patients with stable COPD and 27 patients with exacerbated COPD.97 The MESA group examined the numbers of PECAM, E-selectin, and CD51 EMPs in 104 patients with stable COPD and 76 non-COPD patients.96 These are the only two reported studies of EMP numbers in COPD patients.

Circulating EMPs in patients with stable COPD

Recent studies have indicated that the main causes of death in COPD are cardiovascular events such as ischemic heart diseases and stroke, not respiratory events.98 Vascular abnormalities in the endothelium in both the pulmonary99 and systemic vasculatures100 have been reported in COPD patients. Impaired endothelial function as assessed by flow-mediated dilation of the brachial artery is associated with low FEV₁ in COPD.101 Subclinical arteriosclerosis, as evaluated by carotid intima–media thickness and focal athermanous plaque, is exaggerated early in the disease process of COPD.102 Reduced white matter integrity throughout the brain has been detected by magnetic resonance imaging in COPD patients, suggesting cerebral small vessel injury caused by COPD-associated conditions.103,104 The repair capacity of endothelial progenitor cells is also significantly impaired in the early stage of COPD.97,105 Furthermore, some animal studies have demonstrated apoptosis of pulmonary capillary endothelial cells due to emphysematous changes.11 These reports indicate that endothelial injury is closely connected to the pathophysiology of COPD.

We reported that VE-cadherin EMPs, PECAM EMPs, and E-selectin EMPs were significantly increased in patients with stable COPD compared to ex-smoker controls independent of smoking history, sex, body mass index, and age.82 This increase in PECAM EMPs was confirmed in a larger study performed by the MESA group.96 However, when adjusted for other factors, there were no significant differences in the levels of CD51 EMPs and E-selectin EMPs, although both EMPs tended to increase in COPD in the MESA group’s study. According to the Global initiative for chronic Obstructive Lung Disease (GOLD) stage progression, VE-cadherin EMPs, PECAM EMPs, and E-selectin EMPs were significantly increased in our study, although we could not analyze differences between each stage due to the small sample sizes. The MESA group reported that PECAM EMPs were significantly increased in mild and moderate COPD compared to control subjects in analyses adjusted for other factors; in contrast CD51 EMPs were not significantly elevated and E-selectin EMPs were only elevated in severe COPD. These results indicate that PECAM, VE-cadherin, and E-selectin EMPs are increased in patients with stable COPD compared to healthy controls independent of other factors associated with endothelial injury.

These two studies also examined the relationships between the degree of lung destruction and the numbers of EMPs. PECAM EMPs, E-selectin EMPs, and VE-cadherin EMPs were inversely correlated with parameters of lung functions such as the percent predicted FEV₁. The MESA group also reported that PECAM EMPs were significantly associated with parameters of lung destruction such as percent emphysema (low attenuation area; LAA), pulmonary microvascular perfusion as assessed by magnetic resonance imaging, and diffusing capacity of the lung for carbon monoxide (D_LCO). However, there was no significant correlation between E-selectin EMP levels and these parameters. By contrast, E-selectin EMPs were significantly related to hyperinflation characterized by both increased RV and a higher RV/TLC ratio; no such relationship was observed for PECAM EMPs. These results indicate that endothelial injury combined with impaired mobilization capacity of endothelial progenitor cells97,105 might be involved in the pathogenesis of emphysema and COPD.

Endothelial injury occurs in both the pulmonary and systemic vasculatures in COPD. Thus, EMPs can be released from both the pulmonary vasculatures and systemic vasculatures. To distinguish between EMPs originating from pulmonary and systemic circulation, the absence of vWF82 and the presence of angiotensin-converting enzyme (ACE; CD143)46 on EMPs were examined. vWF is a marker of endothelial cells that is not expressed on pulmonary capillary cells.106,107 Thus, vWF-negative EMPs are of pulmonary capillary origin. The pulmonary capillary endothelium contains abundant ACE. Thus, ACE-positive EMPs are of pulmonary capillary origin. In active smokers with normal spirometry and low D_LCO, approximately 75% of PECAM EMPs were ACE positive, indicating pulmonary capillary origin.46 In stage II COPD patients, approximately 60% of the increased EMPs were vWF negative (Figure 3). In addition, the numbers of EMPs in stage IV COPD patients with severe emphysema were lower than those with mild emphysema, reflecting the reduction of pulmonary capillary vascular beds in emphysema. These results confirmed two facts. First, the increased EMPs in COPD mainly originate from the pulmonary capillary vasculature. Second, the numbers of vWF-negative or ACE-positive EMPs are sensitive markers for the detection of endothelial injury in the pulmonary capillary vasculature.

Multivariable analysis revealed that E-selectin levels were higher in patients with stable COPD with a history of frequent exacerbation (two or more episodes of exacerbation each year) than in COPD patients without frequent exacerbation.82 Unfortunately, the relationship between the number of EMPs and the rate of exacerbation was not analyzed in the MESA study.96 E-selectin EMP levels may reflect ongoing endothelial inflammation. Because exacerbations are associated with accelerated loss of lung function,2–5 we hypothesize that high E-selectin EMP levels led to a rapid loss of lung function in patients with stable COPD with a history of frequent exacerbation.

Circulating EMPs in patients with exacerbated COPD

Recent studies have indicated that an exacerbation episode is connected to the progression of COPD. A history of frequent exacerbation and/or numbers of exacerbation episodes is associated with future rapid FEV₁ decline, increased morbidity, readmission rates, and mortality.108–112 Exacerbation episodes are also associated with emphysema progression, as evaluated by chest computed tomography scans in patients with COPD.113 Although the importance of exacerbation in COPD management is becoming clearer, the diagnosis and evaluation of exacerbation are mainly based on clinical symptoms.

Accumulating evidence suggests that further endothelial injury occurs during exacerbation. For example, flow and nitroglycerin-mediated peripheral vascular dilation are impaired during acute exacerbation.114 In addition, inflammatory responses, particularly platelet activation, are upregulated during exacerbation. Platelet aggregation is exaggerated,115 mean platelet volume is increased,116 and plasma vWF and fibrinogen levels are increased during exacerbation.117 To clarify the influence of COPD exacerbation on the endothelium, we examined the numbers of EMPs during exacerbation.

VE-cadherin, PECAM, and E-selectin EMPs were significantly higher in patients during COPD exacerbation than in stable patients. Interestingly, the majority of the EMPs that were increased during COPD exacerbation were vWF negative (Figure 3), indicating that pulmonary capillary endothelial cells were the main targets of injury during exacerbation. In addition, exacerbation is associated with the progression of emphysema,113 which is connected to endothelial injury in the pulmonary vasculature.11 These reports confirmed that endothelial injury, primarily in pulmonary capillary endothelial cells, occurred during exacerbation.

The trends in the levels of circulating VE-cadherin EMPs, PECAM EMPs, and E-selectin EMPs differed after exacerbation (Figure 3). All EMP levels increased significantly one day after the onset of exacerbation, but after 28 days, the levels of VE-cadherin EMPs and PECAM EMPs remained high, while the level of E-selectin EMPs declined to less than the baseline level. The persistent high VE-cadherin and PECAM EMP levels after 28 days indicate that endothelial injury induced by exacerbation continues even after clinical symptoms disappear. Similar to E-selectin EMP levels, plasma fibrinogen levels also increase during exacerbation and decrease significantly in 4–6 weeks.118–120 Although there are no data to indicate a significant correlation between E-selectin EMP levels and plasma fibrinogen levels, these reports provide additional evidence that E-selectin EMP levels reflect ongoing endothelial inflammation and that VE-cadherin and PECAM EMP levels reflect endothelial injury as a consequence of endothelial inflammation. The decrease in the high E-selectin EMP levels during the early phase of exacerbation to levels lower than the baseline after treatment indicates that inflammation is present on the endothelium even during the stable phase before the onset of exacerbation. Most of the patients who underwent exacerbation received a systemic corticosteroid therapy, however, the role of steroid in the EMP levels is not defined yet. Further analyses are needed to clarify the impact of the COPD drugs on the kinetics of EMPs. Furthermore, drug therapies that ameliorate increased EMP levels may have an effect on prognosis of COPD patients.

Effects of increased EMPs on COPD pathophysiology

Increased numbers of EMPs are observed in patients with stable COPD. The release of EMPs increases further during exacerbation. In addition, COPD patients with a history of frequent exacerbation exhibit high levels of circulating EMPs not only during exacerbation but also in the stable phase. However, the effects of this increase in EMPs on COPD pathophysiology remain unclear. In patients with severe systemic inflammatory syndrome, EMPs are produced and actively bind to leukocytes.121 MPs from human atherosclerotic plaques promote transendothelial migration of monocytes.122 Circulating MPs in patients with myocardial infarction induce endothelial dysfunction.123 Based on these reports, the increased EMPs released from injured pulmonary endothelium might induce further endothelial injury in both the pulmonary vasculature and distant systemic vasculature; this injury might be involved in further lung destruction as well as the increased incidence of cardiovascular diseases in COPD patients in both the stable phase and after exacerbation.108 Because the MPs released in response to various stimuli are heterogeneous, future studies should examine the effects of MPs on the endothelium using MPs isolated from COPD patients. Prospective studies are also needed to clarify the relationship between increased EMP levels and the incidence of cardiovascular diseases.

Technical difficulties with measuring EMPs

There are several technical difficulties reported in the measurement of MPs. For example, there is no clear definition of MPs. The differences between exosomes and MPs remain unclear. Thus, there is no standard protocol for isolating and detecting circulating MPs from the plasma, and the results of microparticle studies are often inconsistent.124 Differences in flow cytometers influence the sensitivity of MP detection. In addition, differences in centrifugation protocols influence the number of MPs. Clear definitions and standardization of protocols are essential.

Conclusion

In this review, we proposed the potential use of circulating MPs, particularly EMPs, as novel biomarkers for COPD (Figure 4). In addition, by comparing subtypes of MPs that are increased in COPD patients, we may be able to reclassify heterogeneous COPD. Furthermore, the relationship between COPD and other MPs, such as platelet-derived MPs, could be an intriguing area of investigation in the future.

Figure 1

Comparison of the size and release mechanism of exosomes and MPs.

Notes: Exosomes are vesicles (40–100 nm in diameter) that are surrounded by a phospholipid bilayer and are released through exocytosis of multivesicular bodies. Thus, on their membranes, exosomes express abundant markers of multivesicular bodies, such as the tetraspanin CD63 and MHC II molecules. MPs are membrane vesicles (100–1,000 nm) that are released by budding or shedding from the plasma membrane of activated or apoptotic cells in response to injury. Thus, markers expressed on the origin cell are also expressed on the MP membrane.

Abbreviations: MP, microparticle; MHC II, major histocompatibility class II.

Figure 2

Location of four EMP markers on ECs.

Notes: VE-cadherin is localized in adherence junctions. PECAM-1 and MCAM are located outside of adherence junctions. In addition, MCAM is expressed not only at cell junctions but also at the apical side of endothelial cells. These three endothelial markers are constitutively expressed on endothelial cells. By contrast, upregulation of E-selectin expression is rapidly induced on endothelial cells when cells are activated.

Abbreviations: EMPs, endothelial microparticles; ECs, endothelial cells; PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial; MPs, microparticles.

Figure 3

EMP levels in patients with exacerbated COPD.

Notes: (A) Comparison of EMP levels and expression of vWF on EMPs between stable and exacerbated Gold II COPD patients. (B) Time courses of EMP levels before, during, and after exacerbation. Adapted by permission from BMJ Publishing Group Limited. Thorax, Takahashi T, Kobayashi S, Fujino N, et al, 67, 1067–1074, copyright 2012.82

Abbreviations: EMPs, endothelial microparticles; COPD, chronic obstructive pulmonary disease; VE, vascular endothelial; PECAM, platelet endothelial cell adhesion molecule; PFP, platelet free plasma; vWF, von Willebrand factor.

Figure 4

EMPs as potential biomarkers for COPD.

Abbreviations: EMPs, endothelial microparticles; COPD, chronic obstructive pulmonary disease.

Table 1

Endothelial markers used for detecting EMPs

	Expression	Localization on ECs	Expression on ECs
CD31: PECAM-1	ECs, platelets, leukocytes	Intercellular junction (outside of adherence junctions)	Constitutively expressed
CD51: integrin αV chain	Platelets, ECs, activated T-cells	Surface	Constitutively expressed
CD62E: E-selectin	Activated ECs	Surface	Low on rested ECs; rapidly upregulated in response to inflammation
CD105: endoglin	ECs, mesenchymal stem cells	Surface	Low on resting ECs; upregulated once angiogenesis begins
CD143: ACE	Pulmonary capillary ECs	Surface	Constitutively expressed
CD144: VE-cadherin	ECs (transiently expressed in fetal liver hematopoietic stem cells)	Adherence junction	Constitutively expressed
CD146: MCAM	ECs, melanoma, smooth muscle cells, dendritic cells, activated T cells	Intercellular junction (outside of adherence junctions) and surface	Constitutively expressed
von Willebrand factor	ECs (not expressed on pulmonary capillary)	Surface (stored in Weibel–Palade bodies of ECs)	Released through exocytosis of Weibel–Palade bodies in response to endothelial activation

Abbreviations: ECs, endothelial cells; EMPs, endothelial microparticles; ACE, angiotensin-converting enzyme; PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial.

Table 2

Numbers of circulating EMPs in various diseases

Cardiovascular diseasesRenal diseasesRespiratory diseasesRisk factor for cardiovascular diseasesSystemic inflammatory diseases

	VE-cadherin EMPs	PECAM EMPs	E-selectin EMPs	MCAM EMPs
Coronary artery disease	↑	↑	↑	?
Acute ischemic stroke	↑a	?	?	?
Renal failure	↑	↑	?	↑
Pulmonary hypertension	↑	↑	↑	?
Obstructive sleep apnea	?	↑	↑	?
Current smoker	?	↑	↑a	?
Hyperlipidemia	?	↑	?	?
Diabetes mellitus	↑	↑	?	?
Obesity	?	↑	?	?
Vasculitis	↑	?	?	↑
Multiple sclerosis	?	↑	?	?
Active thrombotic thrombocytopenic purpura	?	↑	↑	?
Antiphospholipid syndrome	?	↑	?	?
Subarachnoid hemorrhage	?	?	↑	↑
Sepsis	?	?	?	↑
Allograft rejection	?	?	↑	?

Notes:

↑means P<0.05 versus healthy control

?means no previous report;

ameans in moderate to severe stroke.

Abbreviations: PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial; EMPs, endothelial microparticles.

Table 3

Articles comparing two or more EMP subtypes in subjects with pathological conditions

Condition	EMP subtypes	Reference
ST-elevation myocardial infarction	Patients with LAD infarctions versus those with other infarct-related arteries VE-cadherin EMPs: no change PECAM EMPs: ↑ Significant correlation VE-cadherin EMPs: EF, not myocardium at risk PECAM EMPs: myocardium at risk and EF	Atherosclerosis. 2012;221(1):226–23159
Current smoker	Healthy non-smokers versus healthy smokers PECAM EMPs: ↑ E-selectin EMPs: ↓ (CD42b⁻CD62⁺/CD42b⁻CD31⁺ ratio)	Am J Respir Crit Care Med. 2011;184(2):224–23246
End-stage renal disease	Significant correlation VE-cadherin EMPs: brachial artery, ascending aortic SS PECAM EMPs: brachial artery SS	Hypertension. 2007;49:902–908127
Precapillary PH	PH patients versus control VE-cadherin, PECAM, E-selectin EMPs: ↑ Significant correlation VE-cadherin, PECAM EMPs: pulmonary pressure, CI E-selectin EMPs: no correlation with pulmonary pressure, CI	Am J Respir Crit Care Med. 2008;177:1268–1275128
Precapillary PH	PH patients who died or were re-admitted versus patients without events VE-cadherin, PECAM EMPs: no change E-selectin EMPs: ↑ (high E-selectin EMP level: high rate of clinical complications, worse prognosis)	J Heart Lung Transplant. 2009;28:1081–1086129
Short-term withdrawal of CPAP in patients with obstructive sleep apnea	CPAP withdrawal group versus continuing therapeutic CPAP group PECAM EMPs: no change E-selectin EMPs: ↑ (in the CPAP withdrawal group)	Eur Respir J. 2009;33:574–580130
Circulating EMPs in acute ischemic stroke	Moderate to severe ischemic stroke patients versus control Endoglin + EMPs (E + EMPs): ↑ VE-cadherin + EMPs (C + EMPs): ↑ Phosphatidylserine + EMPs (PS + EMPs): ↑ ICAM-1 + EMPs (I + EMPs): ↑ Significant correlation E + EMPs: brain ischemic lesion volume, discharge clinical outcome PS + EMPs: brain ischemic lesion volume I + EMPs: brain ischemic lesion volume C + EMPs: discharge clinical outcome	J Thromb Haemost. 2006;4:1296–1302131
COPD	Stable condition (versus control) VE-cadherin, PECAM, E-selectin EMPs: ↑, MCAM EMPs: no change Exacerbation (versus before exacerbation) VE-cadherin, PECAM, E-selectin EMPs: ↑, MCAM EMPs: no change	Thorax. 2012;67:1067–107482

Abbreviations: LAD, left anterior descending coronary artery; ECs, endothelial cells; ACE, angiotensin-converting enzyme; PECAM, platelet endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VE, vascular endothelial; EMPs, endothelial microparticles; EF, ejection fraction; SS, shear stress; PH, pulmonary hypertension; CI, cardiac index; CPAP, continuous positive airway pressure; COPD, chronic obstructive pulmonary disease.

Footnotes

Disclosure

The authors report no conflicts of interest in this work.

References

1. RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med20071766532555[PubMed][Google Scholar]
2. DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax20025710847852[PubMed][Google Scholar]
3. VestboJEdwardsLDScanlonPDECLIPSE InvestigatorsChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med20113651311841192[PubMed][Google Scholar]
4. KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med20011643358364[PubMed][Google Scholar]
5. CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med20073568775789[PubMed][Google Scholar]
6. BrutscheMHDownsSHSchindlerCSAPALDIA TeamBronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort studyThorax2006618671677[PubMed][Google Scholar]
7. AgustiACalverleyPMCelliBEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigatorsCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res201011122[PubMed][Google Scholar]
8. VestboJRennardSChronic obstructive pulmonary disease biomarker(s) for disease activity needed – urgentlyAm J Respir Crit Care Med20101827863864[PubMed][Google Scholar]
9. HensonPMVandivierRWDouglasISCell death, remodeling, and repair in chronic obstructive pulmonary disease?Proc Am Thorac Soc200638713717[PubMed][Google Scholar]
10. SchmidtEPTuderRMRole of Apoptosis in Amplifying Inflammatory Responses in Lung DiseasesJ Cell Death2010201034153[PubMed][Google Scholar]
11. KasaharaYTuderRMTaraseviciene-StewartLInhibition of VEGF receptors causes lung cell apoptosis and emphysemaJ Clin Invest20001061113111319[PubMed][Google Scholar]
12. KasaharaYTuderRMCoolCDLynchDAFloresSCVoelkelNFEndothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysemaAm J Respir Crit Care Med20011633 Pt 1737744[PubMed][Google Scholar]
13. TsujiTAoshibaKNagaiAAlveolar cell senescence in patients with pulmonary emphysemaAm J Respir Crit Care Med20061748886893[PubMed][Google Scholar]
14. HodgeSHodgeGHolmesMReynoldsPNIncreased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessationEur Respir J2005253447454[PubMed][Google Scholar]
15. VandivierRWHensonPMDouglasISBurying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung diseaseChest2006129616731682[PubMed][Google Scholar]
16. RyterSWChoiAMAutophagy in the lungProc Am Thorac Soc2010711321[PubMed][Google Scholar]
17. PisetskyDSGauleyJUllalAJHMGB1 and microparticles as mediators of the immune response to cell deathAntioxid Redox Signal201115822092219[PubMed][Google Scholar]
18. TheryCOstrowskiMSeguraEMembrane vesicles as conveyors of immune responsesNat Rev Immunol200998581593[PubMed][Google Scholar]
19. GyorgyBSzaboTGPasztoiMMembrane vesicles, current state-of-the-art: emerging role of extracellular vesiclesCell Mol Life Sci2011681626672688[PubMed][Google Scholar]
20. CocucciERacchettiGMeldolesiJShedding microvesicles: artefacts no moreTrends Cell Biol20091924351[PubMed][Google Scholar]
21. NomuraSOzakiYIkedaYFunction and role of microparticles in various clinical settingsThromb Res20081231823[PubMed][Google Scholar]
22. MartinezMCTual-ChalotSLeonettiDAndriantsitohainaRMicroparticles: targets and tools in cardiovascular diseaseTrends Pharmacol Sci20113211659665[PubMed][Google Scholar]
23. RautouPEVionACAmabileNMicroparticles, vascular function, and atherothrombosisCirc Res20111095593606[PubMed][Google Scholar]
24. BoilardENigrovicPALarabeeKPlatelets amplify inflammation in arthritis via collagen-dependent microparticle productionScience20103275965580583[PubMed][Google Scholar]
25. RubinOCanelliniGDelobelJLionNTissotJDRed blood cell microparticles: clinical relevanceTransfus Med Hemother2012395342347[PubMed][Google Scholar]
26. SmalleyDMShemanNENelsonKTheodorescuDIsolation and identification of potential urinary microparticle biomarkers of bladder cancerJ Proteome Res20087520882096[PubMed][Google Scholar]
27. ValentiRHuberVIeroMFilipazziPParmianiGRivoltiniLTumor-released microvesicles as vehicles of immunosuppressionCancer Res200767729122915[PubMed][Google Scholar]
28. MostefaiHAMezianiFMastronardiMLCirculating microparticles from patients with septic shock exert protective role in vascular functionAm J Respir Crit Care Med20081781111481155[PubMed][Google Scholar]
29. BoulangerCMAmabileNTedguiACirculating microparticles: a potential prognostic marker for atherosclerotic vascular diseaseHypertension2006482180186[PubMed][Google Scholar]
30. SidhuSSMengistabATTauscherANLaVailJBasbaumCThe microvesicle as a vehicle for EMMPRIN in tumor-stromal interactionsOncogene2004234956963[PubMed][Google Scholar]
31. MacKenzieAWilsonHLKiss-TothEDowerSKNorthRASurprenantARapid secretion of interleukin-1beta by microvesicle sheddingImmunity2001155825835[PubMed][Google Scholar]
32. WilsonHLFrancisSEDowerSKCrossmanDCSecretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activationJ Immunol2004173212021208[PubMed][Google Scholar]
33. GasserOHessCMiotSDeonCSanchezJCSchifferliJACharacterisation and properties of ectosomes released by human polymorphonuclear neutrophilsExp Cell Res20032852243257[PubMed][Google Scholar]
34. BaroniMPizziraniCPinottiMStimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticlesFASEB J200721819261933[PubMed][Google Scholar]
35. PisetskyDSUllalAJGauleyJNingTCMicroparticles as mediators and biomarkers of rheumatic diseaseRheumatology (Oxford)2012511017371746[PubMed][Google Scholar]
36. MartinezMCTesseAZobairiFAndriantsitohainaRShed membrane microparticles from circulating and vascular cells in regulating vascular functionAm J Physiol Heart Circ Physiol20052883H1004H1009[PubMed][Google Scholar]
37. LeyKLaudannaCCybulskyMINoursharghSGetting to the site of inflammation: the leukocyte adhesion cascade updatedNat Rev Immunol200779678689[PubMed][Google Scholar]
38. LovrenFVermaSEvolving role of microparticles in the pathophysiology of endothelial dysfunctionClin Chem201359811661174[PubMed][Google Scholar]
39. RyterSWChenZHKimHPChoiAMAutophagy in chronic obstructive pulmonary disease: homeostatic or pathogenic mechanism?Autophagy200952235237[PubMed][Google Scholar]
40. TakahashiTKobayashiSFujinoNDifferences in the released endothelial microparticle subtypes between human pulmonary microvascular endothelial cells and aortic endothelial cells in vitroExp Lung Res2013394–5155161[PubMed][Google Scholar]
41. KosmiderBMessierEMChuHWMasonRJHuman alveolar epithelial cell injury induced by cigarette smokePLoS One2011612e26059[PubMed][Google Scholar]
42. BernhardDPfisterGHuckCWDisruption of vascular endothelial homeostasis by tobacco smoke: impact on atherosclerosisFASEB J2003171523022304[PubMed][Google Scholar]
43. LiMYuDWilliamsKJLiuMLTobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophagesArterioscler Thromb Vasc Biol201030918181824[PubMed][Google Scholar]
44. LiCJLiuYChenYYuDWilliamsKJLiuMLNovel proteolytic microvesicles released from human macrophages after exposure to tobacco smokeAm J Pathol2013182515521562[PubMed][Google Scholar]
45. HeissCAmabileNLeeACBrief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide productionJ Am Coll Cardiol2008511817601771[PubMed][Google Scholar]
46. GordonCGudiKKrauseACirculating endothelial microparticles as a measure of early lung destruction in cigarette smokersAm J Respir Crit Care Med20111842224232[PubMed][Google Scholar]
47. SundarIKYaoHRahmanIOxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseasesAntioxid Redox Signal2013181519561971[PubMed][Google Scholar]
48. TuderRMPetracheIPathogenesis of chronic obstructive pulmonary diseaseJ Clin Invest2012122827492755[PubMed][Google Scholar]
49. HelalODefoortCRobertSIncreased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stressNutr Metab Cardiovasc Dis2011219665671[PubMed][Google Scholar]
50. SethiSMaloneyJGroveLWronaCBerensonCSAirway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20061739991998[PubMed][Google Scholar]
51. SeemungalTSykesAICEAD ContributorsRecent advances in exacerbations of COPDThorax20086310850852[PubMed][Google Scholar]
52. MayneEFunderburgNTSiegSFIncreased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expressionJ Acquir Immune Defic Syndr2012594340346[PubMed][Google Scholar]
53. KornekMLynchMMehtaSHCirculating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitisGastroenterology20121432448458[PubMed][Google Scholar]
54. GeSHertelBEmdenSHMicroparticle generation and leucocyte death in Shiga toxin-mediated HUSNephrol Dial Transplant201227727682775[PubMed][Google Scholar]
55. NieuwlandRBerckmansRJMcGregorSCellular origin and procoagulant properties of microparticles in meningococcal sepsisBlood2000953930935[PubMed][Google Scholar]
56. DiamantMTushuizenMESturkANieuwlandRCellular microparticles: new players in the field of vascular disease?Eur J Clin Invest2004346392401[PubMed][Google Scholar]
57. FreyssinetJMCellular microparticles: what are they bad or good for?J Thromb Haemost20031716551662[PubMed][Google Scholar]
58. SinghNVan CraeyveldETjwaMCirculating apoptotic endothelial cells and apoptotic endothelial microparticles independently predict the presence of cardiac allograft vasculopathyJ Am Coll Cardiol2012604324331[PubMed][Google Scholar]
59. JungCSorenssonPSalehNArhedenHRydenLPernowJCirculating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarctionAtherosclerosis20122211226231[PubMed][Google Scholar]
60. NozakiTSugiyamaSKogaHSignificance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart diseaseJ Am Coll Cardiol2009547601608[PubMed][Google Scholar]
61. ErdbrueggerUGrossheimMHertelBDiagnostic role of endothelial microparticles in vasculitisRheumatology (Oxford)2008471218201825[PubMed][Google Scholar]
62. DuvalAHelleyDCapronLEndothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodiesRheumatology (Oxford)201049610491055[PubMed][Google Scholar]
63. JimenezJJJyWMauroLMHorstmanLLSoderlandCAhnYSEndothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activationBr J Haematol20031235896902[PubMed][Google Scholar]
64. CombesVSimonACGrauGEIn vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulantJ Clin Invest1999104193102[PubMed][Google Scholar]
65. AmabileNGuerinAPLeroyerACirculating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failureJ Am Soc Nephrol2005161133813388[PubMed][Google Scholar]
66. FaureVDouLSabatierFElevation of circulating endothelial microparticles in patients with chronic renal failureJ Thromb Haemost200643566573[PubMed][Google Scholar]
67. AmabileNGuerinAPTedguiABoulangerCMLondonGMPredictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot studyNephrol Dial Transplant201227518731880[PubMed][Google Scholar]
68. PirroMSchillaciGPaltricciaRIncreased ratio of CD31+/CD42− microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemiaArterioscler Thromb Vasc Biol2006261125302535[PubMed][Google Scholar]
69. MooreXLMichellDLeeSIncreased carotid intima–media thickness and reduced distensibility in human class III obesity: independent and differential influences of adiposity and blood pressure on the vasculaturePLoS One201381e53972[PubMed][Google Scholar]
70. StepanianABourguignatLHennouSMicroparticle increase in severe obesity: Not related to metabolic syndrome and unchanged after massive weight lossObesity20132122362243[PubMed][Google Scholar]
71. VincentPAXiaoKBuckleyKMKowalczykAPVE-cadherin: adhesion at arm’s lengthAm J Physiol Cell Physiol20042865C987C997[PubMed][Google Scholar]
72. BardinNAnfossoFMasseJMIdentification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesionBlood2001981336773684[PubMed][Google Scholar]
73. ShawSKBambaPSPerkinsBNLuscinskasFWReal-time imaging of vascular endothelial-cadherin during leukocyte transmigration across endotheliumJ Immunol2001167423232330[PubMed][Google Scholar]
74. ConwayDSchwartzMALessons from the endothelial junctional mechanosensory complexF1000 Biol Rep201241[PubMed][Google Scholar]
75. NewmanPJBerndtMCGorskiJPECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamilyScience1990247494712191222[PubMed][Google Scholar]
76. Angelillo-ScherrerALeukocyte-derived microparticles in vascular homeostasisCirc Res20121102356369[PubMed][Google Scholar]
77. PatilSNewmanDKNewmanPJPlatelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagenBlood200197617271732[PubMed][Google Scholar]
78. CicmilMThomasJMLeducMBonCGibbinsJMPlatelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human plateletsBlood2002991137144[PubMed][Google Scholar]
79. FalatiSPatilSGrossPLPlatelet PECAM-1 inhibits thrombus formation in vivoBlood20061072535541[PubMed][Google Scholar]
80. MullerWALeukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory responseTrends Immunol2003246327334[PubMed][Google Scholar]
81. WoodfinAVoisinMBNoursharghSPECAM-1: a multi-functional molecule in inflammation and vascular biologyArterioscler Thromb Vasc Biol2007271225142523[PubMed][Google Scholar]
82. TakahashiTKobayashiSFujinoNIncreased circulating endothelial microparticles in COPD patients: a potential biomarker for COPD exacerbation susceptibilityThorax2012671210671074[PubMed][Google Scholar]
83. WangZYanXCD146, a multi-functional molecule beyond adhesionCancer Lett20133302150162[PubMed][Google Scholar]
84. LehmannJMRiethmullerGJohnsonJPMUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamilyProc Natl Acad Sci U S A1989862498919895[PubMed][Google Scholar]
85. ElshalMFKhanSSTakahashiYSolomonMAMcCoyJPJrCD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral bloodBlood2005106829232924[PubMed][Google Scholar]
86. MaierCLShepherdBRYiTPoberJSExplant outgrowth, propagation and characterization of human pericytesMicrocirculation2010175367380[PubMed][Google Scholar]
87. BlannADWoywodtABertoliniFCirculating endothelial cells. Biomarker of vascular diseaseThromb Haemost2005932228235[PubMed][Google Scholar]
88. BertoliniFShakedYMancusoPKerbelRSThe multifaceted circulating endothelial cell in cancer: towards marker and target identificationNat Rev Cancer2006611835845[PubMed][Google Scholar]
89. BevilacquaMButcherEFurieBSelectins: a family of adhesion receptorsCell1991672233[PubMed][Google Scholar]
90. JimenezJJJyWMauroLMSoderlandCHorstmanLLAhnYSEndothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosisThromb Res20031094175180[PubMed][Google Scholar]
91. SosnoskiDMEmanuelBSHawkinsALChromosomal localization of the genes for the vitronectin and fibronectin receptors alpha subunits and for platelet glycoproteins IIb and IIIaJ Clin Invest198881619931998[PubMed][Google Scholar]
92. KokuboTUchidaHChoiETIntegrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasiaJ Vasc Surg200745Suppl AA33A38[PubMed][Google Scholar]
93. SheppardDRoles of alphav integrins in vascular biology and pulmonary pathologyCurr Opin Cell Biol2004165552557[PubMed][Google Scholar]
94. MinagarAJyWJimenezJJElevated plasma endothelial microparticles in multiple sclerosisNeurology2001561013191324[PubMed][Google Scholar]
95. Bernal-MizrachiLJyWJimenezJJHigh levels of circulating endothelial microparticles in patients with acute coronary syndromesAm Heart J20031456962970[PubMed][Google Scholar]
96. ThomashowMAShimboDParikhMAEndothelial microparticles in mild chronic obstructive pulmonary disease and emphysema. The Multi-Ethnic Study of Atherosclerosis Chronic Obstructive Pulmonary Disease studyAm J Respir Crit Care Med201318816068[PubMed][Google Scholar]
97. TakahashiTSuzukiSKuboHYamayaMKurosawaSKatoMImpaired endothelial progenitor cell mobilization and colony-forming capacity in chronic obstructive pulmonary diseaseRespirology2011164680687[PubMed][Google Scholar]
98. YoungRPHopkinsREatonTEForced expiratory volume in one second: not just a lung function test but a marker of premature death from all causesEur Respir J2007304616622[PubMed][Google Scholar]
99. PeinadoVIPizarroSBarberaJAPulmonary vascular involvement in COPDChest20081344808814[PubMed][Google Scholar]
100. HunninghakeDBCardiovascular disease in chronic obstructive pulmonary diseaseProc Am Thorac Soc2005214449[PubMed][Google Scholar]
101. BarrRGMesia-VelaSAustinJHImpaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) StudyAm J Respir Crit Care Med20071761212001207[PubMed][Google Scholar]
102. IwamotoHYokoyamaAKitaharaYAirflow limitation in smokers is associated with subclinical atherosclerosisAm J Respir Crit Care Med200917913540[PubMed][Google Scholar]
103. RyuCWJahngGHChoiCWMicrostructural change of the brain in chronic obstructive pulmonary disease: a voxel-based investigation by MRICOPD2013103357366[PubMed][Google Scholar]
104. DoddJWChungAWvan den BroekMDBarrickTRCharltonRAJonesPWBrain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging studyAm J Respir Crit Care Med20121863240245[PubMed][Google Scholar]
105. PalangePTestaUHuertasACirculating haemopoietic and endothelial progenitor cells are decreased in COPDEur Respir J2006273529541[PubMed][Google Scholar]
106. MullerAMHermannsMISkrzynskiCNesslingerMMullerKMKirkpatrickCJExpression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitroExp Mol Pathol2002723221229[PubMed][Google Scholar]
107. KawanamiOJinEGhazizadehMMosaic-like distribution of endothelial cell antigens in capillaries and juxta-alveolar microvessels in the normal human lungPathol Int2000502136141[PubMed][Google Scholar]
108. DonaldsonGCHurstJRSmithCJHubbardRBWedzichaJAIncreased risk of myocardial infarction and stroke following exacerbation of COPDChest2010137510911097[PubMed][Google Scholar]
109. ManninoDMThornDSwensenAHolguinFPrevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEur Respir J2008324962969[PubMed][Google Scholar]
110. Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax20056011925931[PubMed][Google Scholar]
111. SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 114181422[PubMed][Google Scholar]
112. PatelARKowlessarBSDonaldsonGCCardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013188910911099[PubMed][Google Scholar]
113. TanabeNMuroSHiraiTImpact of exacerbations on emphysema progression in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20111831216531659[PubMed][Google Scholar]
114. MarchettiNCiccolellaDEJacobsMRHospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilationCOPD2011826065[PubMed][Google Scholar]
115. MaclayJDMcAllisterDAJohnstonSIncreased platelet activation in patients with stable and acute exacerbation of COPDThorax2011669769774[PubMed][Google Scholar]
116. WangRTLiJYCaoZGLiYMean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary diseaseRespirology201318812441248[PubMed][Google Scholar]
117. PolatliMCakirACildagOBolamanAZYeniseyCYeniceriogluYMicroalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbationJ Thromb Thrombolysis200826297102[PubMed][Google Scholar]
118. WedzichaJASeemungalTAMacCallumPKAcute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levelsThromb Haemost2000842210215[PubMed][Google Scholar]
119. KoutsokeraAKiropoulosTSNikoulisDJClinical, functional and biochemical changes during recovery from COPD exacerbationsRespir Med20091036919926[PubMed][Google Scholar]
120. ValipourASchrederMWolztMCirculating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary diseaseClin Sci (Lond)20081157225232[PubMed][Google Scholar]
121. OguraHTanakaHKohTEnhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndromeJ Trauma2004564823830discussion 830–821[PubMed][Google Scholar]
122. RautouPELeroyerASRamkhelawonBMicroparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migrationCirc Res20111083335343[PubMed][Google Scholar]
123. BoulangerCMScoazecAEbrahimianTCirculating microparticles from patients with myocardial infarction cause endothelial dysfunctionCirculation20011042226492652[PubMed][Google Scholar]
124. WitwerKWBuzasEIBemisLTStandardization of sample collection, isolation and analysis methods in extracellular vesicle researchJ Extracell Vesicles20132[Google Scholar]
125. MorelOTotiFMorelNFreyssinetJMMicroparticles in endothelial cell and vascular homeostasis: are they really noxious?Haematologica2009943313317[PubMed][Google Scholar]
126. van der ZeePMBiroEKoYP-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarctionClin Chem2006524657664[PubMed][Google Scholar]
127. BastaracheJAFremontRDKropskiJABossertFRWareLBProcoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndromeAm J Physiol Lung Cell Mol Physiol20092976L1035L1041[PubMed][Google Scholar]
128. AmabileNHeissCRealWMCirculating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertensionAm J Respir Crit Care Med20081771112681275[PubMed][Google Scholar]
129. AmabileNHeissCChangVIncreased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patientsJ Heart Lung Transplant2009281010811086[PubMed][Google Scholar]
130. AyersLFerryBCraigSNicollDStradlingJRKohlerMCirculating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoeaEur Respir J2009333574580[PubMed][Google Scholar]
131. SimakJGeldermanMPYuHWrightVBairdAECirculating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcomeJ Thromb Haemost20064612961302[PubMed][Google Scholar]